People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Presidio Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $72.6M | $742.2M | 2009 |
| Mid-Atlantic BioTherapeutics, Inc. | — | Biotechnology | Series A | $5.9M | $23.3M | 2018 |
David Jobes at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Jobes on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Srinivas Akkaraju | 1 | 10 |
| Kenneth Galbraith | 1 | 6 |
| Robert Williamson | 1 | 5 |
| Daniel Perez | 1 | 5 |
| Andrew Katz | 1 | 4 |
| Felix Baker | 1 | 4 |
| Nathaniel Brown | 1 | 2 |
| Rodney Ferguson | 1 | 2 |
| H. Thomas F. Anderton | 1 | 1 |
| Leo Redmond | 1 | 1 |
| Kelvin F. Neu | 1 | 1 |
| Eric F. Ruby | 1 | 1 |
| H. Daniel Perez | 1 | 1 |
| Leping Li | 1 | 1 |
| Richard F. Colonno | 1 | 1 |
| Jack Obijeski | 1 | 1 |
| Omar Haffar | 1 | 1 |
| John Obijeski | 1 | 1 |
| Richard Colonno | 1 | 1 |
| Nat Brown | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.